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Abstract
Loss-of-function variants in the low-density lipoprotein receptor-related protein 10 (LRP10) gene have been associated with 
autosomal-dominant Parkinson’s disease (PD), PD dementia, and dementia with Lewy bodies (DLB). Moreover, LRP10 
variants have been found in individuals diagnosed with progressive supranuclear palsy and amyotrophic lateral sclerosis. 
Despite this genetic evidence, little is known about the expression and function of LRP10 protein in the human brain under 
physiological or pathological conditions. To better understand how LRP10 variants lead to neurodegeneration, we first per-
formed an in-depth characterisation of LRP10 expression in post-mortem brains and human-induced pluripotent stem cell 
(iPSC)-derived astrocytes and neurons from control subjects. In adult human brain, LRP10 is mainly expressed in astrocytes 
and neurovasculature but undetectable in neurons. Similarly, LRP10 is highly expressed in iPSC-derived astrocytes but 
cannot be observed in iPSC-derived neurons. In astrocytes, LRP10 is present at trans-Golgi network, plasma membrane, 
retromer, and early endosomes. Interestingly, LRP10 also partially co-localises and interacts with sortilin-related receptor 
1 (SORL1). Furthermore, although LRP10 expression and localisation in the substantia nigra of most idiopathic PD and 
DLB patients and LRP10 variant carriers diagnosed with PD or DLB appeared unchanged compared to control subjects, 
significantly enlarged LRP10-positive vesicles were detected in a patient carrying the LRP10 p.Arg235Cys variant. Last, 
LRP10 was detected in Lewy bodies (LB) at late maturation stages in brains from idiopathic PD and DLB patients and in 
LRP10 variant carriers. In conclusion, high LRP10 expression in non-neuronal cells and undetectable levels in neurons of 
control subjects indicate that LRP10-mediated pathogenicity is initiated via cell non-autonomous mechanisms, potentially 
involving the interaction of LRP10 with SORL1 in vesicle trafficking pathways. Together with the specific pattern of LRP10 
incorporation into mature LBs, these data support an important mechanistic role for disturbed vesicle trafficking and loss of 
LRP10 function in neurodegenerative diseases.
Keywords LRP10 · Parkinson’s disease (PD) · Dementia with Lewy bodies (DLB) · Vesicle trafficking · Astrocytes · Lewy 
bodies
Introduction
Parkinson’s disease (PD) and dementia with Lewy bod-
ies (DLB) are common neurodegenerative disorders 
strongly affecting the ageing population worldwide [27, 
85]. Cardinal motor features of PD include bradykinesia, 
rigidity and rest tremor [12, 69]. These motor signs are 
usually preceded by non-motor manifestations such as 
olfactory dysfunction, rapid eye movement (REM) sleep 
behaviour disorder, depression, and constipation [12, 69]. 
Additionally, over the course of the disease, cognitive 
impairment also develops with progression to dementia 
in up to 80% of the patients [1, 36, 52]. DLB is clini-
cally defined by a gradual cognitive decline as the initial 
manifestation, followed by parkinsonism in over 85% of 
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cases [59]. Although PD and DLB differ in the temporal 
sequence of prominent clinical symptoms, both are neu-
ropathologically characterised by neuronal loss and the 
formation of intracellular α-synuclein-containing inclu-
sions in surviving neurons, termed Lewy bodies (LB) and 
Lewy neurites (LN) [31].
In addition to overlapping clinical and neuropathologi-
cal features, rare, highly penetrant pathogenic variants in 
SNCA (α-synuclein) [43, 68, 92] and LRRK2 (leucine-rich 
repeat kinase 2) [65, 94] have been identified in patients 
with phenotypes ranging from familial PD to DLB. 
Furthermore, heterozygous variants in GBA (glucocer-
ebrosidase) are a strong risk factor for the development 
of both PD and DLB [61, 77]. The recently discovered 
pathogenic variants in LRP10 (low-density lipoprotein 
receptor-related protein 10) associated with autosomal-
dominant, inherited forms of PD, PD dementia (PDD) and 
DLB, further strengthen the evidence of the overlapping 
genetic bases in the Lewy body disorders (LBD) [70, 86]. 
Moreover, the association of LRP10 variants with progres-
sive supranuclear palsy (PSP) [87] and amyotrophic lateral 
sclerosis (ALS) [63], together with the data showing that 
LRP10 is a driver of a specific molecular subtype of Alz-
heimer’s disease (AD) [62], provide evidence of potential 
mechanistic roles for LRP10 across a broader spectrum of 
neurodegenerative diseases.
The physiological roles of LRP10 and how its defects 
contribute to the pathogenesis of these major neurode-
generative disorders associated with parkinsonism and 
dementia remain mostly unknown. Previous studies using 
overexpression models linked LRP10 to vesicle traffick-
ing, showing its localisation at the plasma membrane, 
endosomes, trans-Golgi network, and a partial overlap 
with the retromer complex [15, 17, 18, 26, 70]. However, 
the cellular and subcellular localisation of endogenous 
LRP10 protein in the central nervous system (CNS) dur-
ing normal ageing or disease has not yet been studied.
To gain more insight into the physiological and path-
ological role of LRP10 and how its loss-of-function is 
mechanistically involved in the pathogenesis of PD, PDD, 
and DLB, we performed an in-depth characterisation of 
endogenous LRP10 expression in human-induced pluri-
potent stem cell (iPSC)-derived astrocytes and neurons, 
and human post-mortem brains from control subjects, idi-
opathic PD and DLB cases, and LRP10 variant carriers 
diagnosed with PD or DLB, by biochemical analyses and 
detailed multi-label laser scanning confocal microscopy 
using knockout (KO) validated LRP10 antibodies target-
ing different LRP10 protein domains [70, 86]. In addi-
tion to a detailed description of LRP10 localisation in the 
ageing and diseased brain, our study also provides evi-




We included post-mortem brain tissue specimens from 
28 donors. The demographics, clinical, and neuropatho-
logical characteristics of all donors are listed in the 
Online Resource Table 1. Brain tissue specimens from 
27 donors were provided by the Netherlands Brain Bank 
(NBB), Netherlands Institute for Neuroscience, Amster-
dam. Brain specimens from Patient-III were obtained 
from the Laboratory of Neuropathology—the Institute of 
Neurological Sciences of Bologna (ISNB), Italy. Ethical 
approval for the NBB procedures and forms was given 
by the Medical Ethics Committee of the VU University 
Medical Center (Amsterdam, the Netherlands). Autopsies 
are performed by the NBB at the designated premises of 
the VU Medical Center in Amsterdam, the Netherlands. 
Autopsy procedures and tissue collection at both centres 
were performed in accordance with the Code of Conduct 
for Brain Banking [41] and Declaration of Helsinki (1964 
and its later amendments). For both centres, informed 
consent for brain autopsy, and the use of the tissue and 
clinical information for research purposes was obtained 
from all individual participants included in this study or 
from the next of kin. Clinical and pathological features 
of a total of five donors carrying rare, pathogenic vari-
ants in LRP10 included in this study are summarized in 
the Online Resource Table 1. Briefly, patient I carrying 
a heterozygous LRP10 c.451C>T (p.Arg151Cys) variant 
was clinically diagnosed with AD and showed intermedi-
ate AD-type pathology and cortical Lewy pathology fit-
ting with DLB upon neuropathological examination [86]. 
A heterozygous LRP10 variant c.632dupT (p.Ala212Ser 
fs*17) was identified in patient II who was clinically diag-
nosed with PD and mild cognitive impairment, and on 
neuropathological examination showed Lewy pathology 
and mild AD-type pathology [70]. A heterozygous LRP10 
variant c.703C>T (p.Arg235Cys) was identified in patient 
III who was clinically diagnosed with PDD and on neu-
ropathological examination showed Lewy pathology and 
mild AD-type pathology [70]. Patient IV is a carrier of a 
LRP10 c.1357G>A (p.Gly453Ser) and was clinically diag-
nosed with DLB and designated as mixed AD/LBD upon 
neuropathological diagnosis [86]. Finally, an in-frame 
deletion in LRP10, c.1549_1551delAAT (p.Asn517del) 
was identified in patient V who was clinically and neuro-





Details of all commercial primary antibodies used in this 
study are listed in the Online Resource Table 2. Poly-
clonal sheep anti-LRP10 (LRP10-CT) was generated in 
collaboration with Medical Research Council (MRC) Pro-
tein Phosphorylation and Ubiquitylation Unit Reagents, 
University of Dundee (MRC PPU Reagents, DA058). 
Secondary antibodies used for immunocytochemistry and 
immunohistochemistry include: Alexa  Fluor® 488 donkey 
anti-rabbit/mouse/sheep/goat; Alexa  Fluor® 594 donkey 
anti-rabbit/mouse, Alexa  Fluor® 647 goat anti-guinea pig 
(all from Jackson ImmunoResearch Laboratories). Second-
ary antibodies used for Western blotting include:  IRDye® 
680 donkey anti-mouse/rabbit (LI-COR Biosciences) 
and Alexa  Fluor® donkey anti-sheep (Jackson ImmuneR-
esearch Laboratories).
Cloning
To clone LRP10 expression construct, the MGC human 
LRP10 sequence-verified cDNA was subcloned from the 
human LRP10-pCR4-TOPO plasmid (Dharmacon, 8322768) 
into the pcDNA™3·1/V5-His-TOPO® with a stop codon 
interrupting the expression of the existing V5 tag. Another 
V5 tag was introduced into the N-terminal position relative 
to the LRP10 insert.
For SORL1 cloning, the human SORL1 sequence-veri-
fied cDNA was subcloned from the SORL1-pCR-XL-TOPO 
plasmid (Source bioscience, 9021168) into the pcDNA™3·1/
V5-His-TOPO® replacing the existing V5 tag. All expression 
constructs were verified by Sanger sequencing.
Cell culture
HEK293T cells (ATCC ® CRL-3216™) were maintained in 
growth medium [DMEM (Lonza), 10% (v/v) FBS (Sigma-
Aldrich)] at 37 °C/5%CO2. HuTu 80 cells (ATCC ® HTB-
40™) were maintained in growth medium [DMEM/F-12 
(Gibco), 10% (v/v) FBS] at 37 °C/5%  CO2.
CRISPR/Cas9 LRP10 knockout in HEK293T and HuTu 
80 cells
For CRISPR/Cas9-mediated KO, 20 bp single guide RNA 
(sgRNA) targeting LRP10 exon 1 was selected using CHOP-
CHOP web tool (http:// chopc hop. cbu. uib. no) [46]. sgRNA 
with the highest score was cloned into the pSpCas9-(BB)-
2A-GFP (Addgene, 48138) plasmid. Briefly, sense and anti-
sense oligonucleotides (5′-P-CAC CGC GTT TCG GTT CTT 
ACC AAG G & 5′-P-AAA CCC TTG GTA AGA ACC GAA 
ACG G, Integrated DNA Technologies) with BbsI overhangs 
were synthesized and annealed. Annealed oligonucleotides 
were cloned into the BbsI (NEB) digested pSpCas9-(BB)-
2A-GFP plasmid. All constructs were verified by Sanger 
sequencing. Cells were transfected with the pSpCas9-
(BB)-2A-GFP plasmid containing sgRNA using GeneJuice 
transfection reagent (Merck) according to the manufactur-
er’s specifications. After 48 h, cells were dissociated with 
Trypsin–EDTA (Gibco). GFP-positive cells were sorted as 
single cells into 96-well plates with the BD FACSAria™ III 
cell sorter. Recovered clones were expanded as independ-
ent clones and genotyped. Primers flanking LRP10 exon 1 
(FW: CAA AGT TTG GCC CGA AGA GG, RV: GGG CAG 
GCA GGA TAG AGT GC) were used for PCR amplification. 
PCR products were Sanger sequenced and analysed for the 
presence of INDELs.
Generation and characterisation of human iPSC 
lines
The control line was derived from dermal fibroblasts of a 
healthy male donor at the age of 57. These cells were repro-
grammed and characterised as described earlier [70, 83]. 
All study procedures were approved by the medical ethical 
committee of Erasmus MC, conformed to the principles of 
the WMA Declaration of Helsinki and the Department of 
Health and Human Services Belmont report. Participating 
subjects provided written informed consent for the use of the 
material for research purposes.
Generation of neural progenitor cells 
and differentiation into ventral midbrain 
dopaminergic neurons and astrocytes
Neural progenitor cells were created via inhibition of both 
BMP and TGFβ signalling (SMAD) and stimulation of 
canonical WNT and SHH signalling pathways in free float-
ing embryoid bodies according to published protocols [71] 
with minor modifications as described previously [70]. 
Briefly, iPSC were detached from mouse embryonic fibro-
blasts (MEF) using 2 mg/mL collagenase IV (Gibco). Pieces 
of colonies were resuspended in human Embryonic Stem 
Cell medium [hESC, 80% DMEM/F-12, 20% KnockOut 
Serum Replacement, 1% l-glutamine, 1% Penicilin-Strep-
tomycin, 1% MEM-NEAA (all from Thermo Fisher Scien-
tific), and 0.0007% 2-β-Mercaptoethanol (Sigma-Aldrich)] 
supplemented with 10 µM SB-431542 (Tocris), 1 µM dor-
somorphin (Abcam), 3 µM CHIR99021 (CHIR, Sigma), 
and 0.5 µM Purmorphamine (PMA, Stem Cell Technolo-
gies). Clumps of cells were transferred to 10 cm Petri dishes 
and were cultured in suspension for a total of 6 days on a 
shaker at 80 RPM at 37 °C/5%  CO2. On day 2, medium 
was replaced by N2B27 medium [DMEM/F-12 – Neuroba-
sal in 1:1 ratio, 1:100 B27 w/o Vitamin A, 1:200 N2, 1% 
Penicilin-Streptomycin (all from Thermo Fisher Scientific)] 
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supplemented with 10 µM SB-431542, 1 µM dorsomorphin, 
3 µM CHIR, and 0.5 µM PMA. On day 4, medium was 
changed to N2B27 supplemented with 3 µM CHIR, 0.5 µM 
PMA, and 150 µM Ascorbic Acid (AA, Sigma). On day 
6, embryoid bodies showing neuroepithelial development 
were selectively taken up, triturated into smaller pieces, 
and plated on  Corning®  Matrigel® coated 12-well plates in 
N2B27 medium supplemented with 3 µM CHIR, 200 µM 
AA, and 0.5 µM PMA. Cell splits were performed at 1:10 
ratio. From the sixth passage, 0.5 µM PMA was replaced 
by 0.5 µM Smoothened Agonist (SAG, Abcam). Cells were 
passaged at least five times before final differentiations. For 
ventral midbrain neuronal differentiation, neural progenitors 
were dissociated with accutase (Sigma) at room tempera-
ture (RT), resuspended, and plated (50.000 cells/well) on 
 Corning®  Matrigel® and 0.1 mg/mL poly-d-lysine (Sigma) 
coated 18 mm glass coverslips in 12-well plates in N2B27 
medium supplemented with 1 ng/mL GDNF (PeproTech), 
2 ng/mL BDNF (PeproTech), 200 µM AA, and 0.5 µM SAG 
for a duration of 6 days. Medium was changed every other 
day. After 6 days, cells were refreshed with N2B27 medium 
containing 1 ng/mL GDNF, 2 ng/mL BDNF, 200 µM AA, 
1 ng/mL TGF-β3, 5 ng/mL ActivinA (Stem Cell Technolo-
gies). ActivinA concentration was lowered to 2 ng/mL for 
the subsequent feedings. Medium was changed every other 
day. Neuronal cultures reached mature stage after 3 weeks 
of differentiation. For directed astrocyte differentiation, cells 
were cultured for at least 8 weeks. Briefly, neural progenitors 
were cultured on  Corning®  Matrigel® coated 12-well plates 
for 2 days in N2B27 medium supplemented with 10 ng/mL 
FGF-basic (PeproTech) and 10 ng/mL EGF (PeproTech). 
After 2 days, this medium was switched to N2 medium 
(Advanced DMEM/F-12, 1% N2, 1% Penicilin-Streptomy-
cin, 4% FBS) supplemented with 10 ng/mL CNTF (Pep-
roTech) for 2 weeks. Throughout the whole differentiation 
procedure, astrocyte cultures were split using accutase when 
they reached 80–90% confluence. After CNTF withdrawal, 
cells were expanded for several weeks in N2 medium with 
10 ng/mL EGF. One week before terminating cultures, cells 
were treated with 500 µM dbcAMP in N2 medium.
RNA extraction from cultured cells and brain tissue
Total RNA from cultured cells was isolated using the RNe-
asy Mini Kit (Qiagen) as recommended by the manufac-
turer. Total RNA from substantia nigra of non-demented 
controls (N = 6, Online Resource Table 1, NDC VI-XI) and 
PD patients (N = 6, Online Resource Table 1, PD IV-IX) was 
isolated using a combination of TRIzol™ (Sigma-Aldrich) 
and column isolation protocols. Briefly, TRIzol™ was added 
to substantia nigra pieces that were cut using cryostat from 
frozen at autopsy brain tissues. Tissue was disrupted using 
rotor–stator homogenizer and then incubated 5 min at RT. 
After incubation, chloroform (Sigma) was added, and the 
tube was shaken vigorously by hand for 15 s. The mix was 
incubated for 15 min at RT and subsequently centrifuged at 
13,000 RPM at 4 °C. Clear, upper aqueous phase was col-
lected and mixed in 0.53 volume of RNAse-free 70% etha-
nol. The mix was incubated for 5 min at RT. The samples 
were then transferred to the HighBind™ RNA Mini Column 
(Omega BIO-TEK). The isolation was proceeded according 
to the E.Z.N.A. Total RNA kit I—Animal Tissue Protocol 
(Omega BIO-TEK). For each sample, on-membrane DNase 
I (RNase-Free DNase Set, Qiagen) digestion was performed 
according to the manufacturer’s protocol. The integrity of 
the total RNA was assessed using agarose gel stained with 
GelRed™ (Biotium). Sharp, clear 28S and 18S rRNA bands 
without smearing indicated intact RNA. Spectrophotomet-
ric analysis of extracted RNA using NanoDrop 2000/2000c 
measured 260/280 values of ~ 2.0.
Reverse transcription and quantitative PCR
For the cDNA synthesis, 0.5 µg of the total RNA was used 
with random hexamers using  SuperScript® III First-Strand 
Synthesis System (Thermo Fisher Scientific) followed by 
RNase H digestion. qPCR using iTaq Universal SYBR 
Green Supermix (Bio-Rad) was performed using ~ 100 ng 
cDNA with the following cycling conditions: 3 min at 95 °C 
(initial denaturation), 40 cycles of 5 s at 95 °C, and 30 s at 
60 °C. Data analysis was performed using CFX Manager™ 
software 3.0 (Bio-Rad). Briefly, the normalized expression 
of each target gene was calculated using the delta–delta Cq 
method [54]. Relative LRP10 mRNA levels were determined 
after normalisation to the geometric mean of the following 
housekeeping genes: COPS5, CLK2, and RNF10. Primers 
were designed using Primer3 (v. 0.4.0) online tool (https:// 
bioin fo. ut. ee/ prime r3-0. 4.0/) and are listed in the Online 
Resource Table 3.
Western blotting
Protein lysates were obtained after washing the cells with 
PBS and subsequently adding protein lysis buffer [50 mM 
Tris–Cl (pH 7.4), 100 mM NaCl, 1.0%  IGEPAL® CA-630 
(all from Sigma-Aldrich)] containing protease inhibitors 
 Complete® and  Pefabloc® SC (both from Merck). Lysates 
were snap frozen, thawed on ice and cleared by centrifuga-
tion at 13,000 RPM for 10 min at 4 °C. Lysates were mixed 
with 4 × sample buffer [8% SDS, 20% v/v glycerol, 0.002% 
bromophenolblue, 62.5 mM Tris–Cl (pH 6.8)] supplemented 
with 100 mM dithiothreitol (DTT) and incubated for 10 min 
at 95 °C. Proteins were separated on 4–15% Criterion TGX 
precast gels (Bio-Rad), and transferred to nitrocellulose 
membranes using the Trans-Blot® Turbo™ Transfer Sys-
tem (Bio-Rad). Blots were blocked using 5% non-fat dry 
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milk (Blotto, Santa Cruz Biotechnologies) in PBS for 1 h 
at RT. Primary antibody incubations were performed over-
night at 4 °C in blocking buffer. After washing in PBS, 0.1% 
v/v  TWEEN® 20, blots were incubated for 1 h at RT with 
fluorescently conjugated secondary antibodies (LI-COR 
Biosciences or Jackson ImmuneResearch). After washing 
in PBS, 0.1% v/v  TWEEN® 20, blots were imaged using 
the Odyssey CLx Imaging system and analysed with Image 
Studio™ Lite Ver 5.2 (both from LI-COR Biosciences).
Co‑immunoprecipitation
HEK293T cell lines were plated on 10 cm dishes and trans-
fected with V5-tagged LRP10 and SORL1 expression con-
structs using  GeneJuice® transfection reagent according to 
manufacturer’s specifications. After 48 h, protein lysates 
were collected, and protein concentrations were determined 
via Pierce™ BCA Protein Assay Kit (Thermo Fisher Sci-
entific). For co-immunoprecipitation, 20 μL of Pierce™ 
Protein G Magnetic Beads (Thermo Fisher Scientific) were 
washed three times with washing buffer [50 mM Tris–Cl (pH 
7.4), 0.5 M NaCl, 0.05% v/v  TWEEN® 20] and incubated 
with 400 μg of protein lysate in a final volume of 600 μL for 
1 h at 4 °C. Beads were magnetized and discarded. 20 μL of 
fresh beads were washed and incubated with 2 μg of anti-
body for 10 min at RT. Beads were washed three times with 
washing buffer and incubated with precleared protein lysates 
overnight at 4 °C. Beads were washed three times with wash-
ing buffer supplemented with 0.05% v/v  IGEPAL® CA-630 
and eluted with 10 μL of 2 × sample buffer [4% SDS, 10% 
v/v glycerol, 0.001% bromophenolblue, 62.5 mM Tris–Cl 
(pH 6.8)] supplemented with 100 mM dithiothreitol (DTT) 
for 10 min at 95 °C. Samples were analysed by Western 
blotting. Antibodies used for pulldown: mouse anti-SORL1 
(BD Biosciences, 612633), sheep anti-LRP10 (MRC PPU 
Reagents, DA058), and Mouse Gamma Globulin (Jackson 
ImmunoResearch Laboratories, 015-000-002) used as a 
negative control in place of a primary antibody to evaluate 
any non-specific binding.
Immunocytochemistry on iPSCs
Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) 
for 10 min, and then washed with PBS. After washing, cells 
were incubated in a blocking buffer [50 mM Tris.HCl (pH 
7.4), 0.9% NaCl, 0.25% gelatine, 0.2% Triton™ X-100] con-
taining primary antibody overnight at 4 °C. Next day, cells 
were washed with PBS buffer containing 0.05%  TWEEN® 
20. Cells were then incubated for 1 h with appropriate Alexa 
 Fluor® antibodies (all Jackson ImmunoResearch Laborato-
ries) at RT. After washing off secondary antibodies with 
PBS-TWEEN® 20 buffer, cells were mounted with Pro-
Long Gold with DAPI (Invitrogen). To fluorescently label 
endogenous LRP10 at the plasma membrane, 10-week-old 
iPSC-derived astrocytes were washed twice with ice-cold 
DMEM and subsequently incubated for 2 h on ice with ice-
cold DMEM (Gibco) containing rabbit anti-LRP10 antibody 
(Sino Biological, 13228-T16). Next, cells were washed twice 
with ice-cold DMEM, fixed with 4% paraformaldehyde, and 
processed for staining with Alexa  Fluor® 488 antibody. Sec-
ondary only was used as a negative control. All stainings 
were imaged with Leica SP5 AOBS confocal microscope. 
Scanning was done with a pixel size of 0.12 µm and with 
a scan size of 2048 × 2048 pixels at 400 Hz. For z-stack 
images, 0.35 µm steps in the z-direction were taken. The 
pinhole size was set to 1 airy unit (AU). Sections were irra-
diated with the following lasers: 405 diode UV, argon laser, 
DPSS 561, HeNe 633, depending on fluorophore combina-
tion. Each image was detected on the spectral PMT detector 
with an HCX PL APO CS 40 ×/1.25 or HCX PL APO CS 
63 ×/1.4 lens.
Immunohistochemistry on brain specimens
Immunohistochemistry on formalin-fixed, paraffin-embed-
ded (FFPE) human brain samples was carried on 6–8 μm 
paraffin-embedded tissue sections from different brain 
regions (substantia nigra, medial frontal gyrus (F2), tem-
poral pole, hippocampus). Sections were deparaffinized 
in xylene (Merck) for a total of 10 min and rehydrated in 
graded series of ethanol. Heat-induced antigen retrieval in 
a pressure cooker was applied to slides destined for LRP10 
(Sino Biological, 13228-T16) staining. Slides were boiled 
in 10 mM sodium citrate buffer (pH 6.0) in autoclave at 
121 °C for 20 min. To block endogenous peroxidase activ-
ity, tissue sections were quenched with PBS with 0.6%  H2O2 
for 30 min. Subsequently, sections were incubated with a 
blocking buffer [PBS, 5% milk (w/v, Nutricia)] for 30 min. 
Tissue sections were stained overnight at 4 °C with rabbit 
anti-LRP10 (SinoBiological, 13228-T16). Next day, sections 
were washed three times with PBS-0.1%  TWEEN® 20. Sec-
tions were then incubated with polyHRP secondary antibody 
(polyHRP anti Ms/Rb IgG, BrightVision) at RT for 1 h. To 
fluorescently label LRP10, sections were incubated for 4 min 
at RT with 1:50 dilution of tetramethylrhodamine–tyramide 
in TSA PLUS amplification buffer (all Perkin-Elmer). Sec-
tions were immediately washed with PBS-0.1%  TWEEN® 
20. Endogenous fluorescence was quenched with 0.1% 
(w/v) Sudan Black B (Sigma) in 70% ethanol for 5 min. 
For double labelling with various cellular markers, sec-
tions were exposed again to an antigen retrieval method as 
recommended by antibody manufactures and stained with 
a primary antibody overnight 4 °C. Sections were washed 
with PBS-0.1%TWEEN® 20 buffer and incubated with an 
appropriate secondary Alexa  Fluor® antibodies (all from 
Jackson ImmunoResearch Laboratories) for 1 h at RT. After 
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washing off secondary antibodies with PBS-0.1%  TWEEN® 
20 buffer, sections were mounted with ProLong Gold with 
DAPI. Scanning was done with a pixel size of 0.12 µm and 
with a scan size of 2048 × 2048 pixels at 400 Hz. For z-stack 
images, 0.35 µm steps in the z-direction were taken. The 
pinhole size was set to 1 airy unit (AU). Sections were irra-
diated with the following lasers: 405 diode UV, argon laser, 
DPSS 561, HeNe 633, depending on fluorophore combina-
tion. Each image was detected on the spectral PMT detector 
with an HCX PL APO CS 40 ×/1.25 or HCX PL APO CS 
63 ×/1.4 lens.
LRP10 and α‑synuclein double labelling using 
immunohistochemistry on FFPE brain specimens
After deparaffinization and rehydration, tissue sections 
were first exposed to 80% formic acid (Sigma) for 5 min, 
permeabilized, blocked as mentioned above, and incubated 
with 1:100 mouse monoclonal anti-α-synuclein (clone 
42/α-Synuclein, BD Bioscience, 610786) overnight at 4 °C. 
Sections were then incubated with polyHRP secondary anti-
body (polyHRP anti Ms/Rb IgG, BrightVision) at RT for 
1 h. To fluorescently label α-synuclein, sections were incu-
bated for 4 min at RT with 1 in 50 fluorescein-tyramide in 
TSA PLUS amplification buffer (all Perkin-Elmer). To label 
LRP10 and to strip α-synuclein primary antibody, sections 
were then exposed again to heat-induced antigen retrieval in 
Tris–EDTA buffer (10 mM Tris Base, 1 mM EDTA, 0.05% 
 TWEEN® 20, pH 9.0) and incubated with 1:100 sheep anti-
LRP10 (MRC PPU Reagents, DA058) overnight at 4 °C. 
Sections were washed with PBS-TWEEN® 20 buffer and 
incubated with donkey anti-sheep Alexa  Fluor® 647 (Jack-
son ImmunoResearch Laboratories) for 2 h at RT. Stainings 
were imaged with Leica SP5 AOBS confocal microscope 
(Leica Microsystems). Each image was detected on the spec-
tral PMT detector with an HCX PL APO CS 40x/1.25 or 
HCX PL APO CS 63x/1.4 lens. For 3D volume renderings, 
stainings were imaged with STELLARIS 5 confocal micro-
scope (Leica Microsystems) using a built-in LIGHTNING 
detection technology for super-resolution confocal imaging. 
Scanning was done with a pixel size of 0.029 µm with a scan 
size of 1080 × 1080 pixels at 400 Hz. For z-stack images, 
0.125 µm steps in the z-direction were taken. The pinhole 
size was set to 499.69 mAU. Sections were irradiated with 
the following laser lines: 405, 488, 638. Each image was 
detected on 3 × spectral HyD S detector using HC PL APO 
CS2 63 ×/1.4 lens. The appropriate spectra were defined by 
the ImageCompass software (Leica Microsystems).
Image analysis
All images were processed using FIJI software. Man-
ders Overlap Coefficient (MOC) was calculated using 
Colocalization Threshold plug-in available in FIJI. The 
thresholds were defined using Costes automatic threshold 
searching [22]. To measure the LRP10-positive vesicle area 
in post-mortem brain tissue, we acquired 6–9 Z-stack images 
of the substantia nigra with a scan size of 4096 × 4096 and a 
pixel size of 0.946 µm. We only included glial cells residing 
in the SN based on the presence of LRP10-positive vesicles. 
All the glial cells were selected, irrespective of the presence 
of any pathological feature. We then performed automated 
batch analysis using FIJI batch processor with a self-gener-
ated macro-code on maximum projection regions of interests 
(ROIs) containing single cells expressing LRP10-positive 
vesicles. First, we subtracted background noise using the 
rolling ball algorithm with a radius of 10. Gaussian blur 
filter (σ = 2.0) was applied to all images. Vesicle segmenta-
tion was then performed using the auto threshold method 
developed by Otsu [64]. Images were converted to masks, 
and watershed was applied to segment adjacent structures. 
Segmented LRP10-positive vesicles were then analysed with 
the Analyze Particles plug-in. Very small particles with a 
size below 0.5 µm2 were discarded from the analysis. For 
quantitative characterisation of iPSC-derived progenitors, 
vmDAN, and astrocytes, fluorescence-based thresholding 
was applied for each cell-specific marker. Cells were consid-
ered positive for each marker when their fluorescent signal 
was above that threshold. To measure the percentages of 
LRP10 immunoreactivity in various types of Lewy pathol-
ogy, we acquired Z-stack images and only selected neu-
romelanin-containing dopaminergic neurons of the SN. For 
the analysis, we considered neurons with morphologically 
diverse α-synuclein immunoreactive deposits within the neu-
ronal soma. We identified diverse types of α-synuclein accu-
mulations as described by Kuusisto et al. [44] and grouped 
the cells based on their shared α-synuclein immunostaining 
profile. For the analysis of LRP10 regional expression in the 
adult human brain tissue from non-demented subjects, we 
acquired Z-stack images and selected for astrocytes based 
on the expression of the astrocyte-specific marker S100β 
in the substantia nigra, temporal pole, and throughout the 
hippocampus. Fluorescence-based thresholding was applied 
for S100β. Cells were included in the analysis when their 
fluorescent signal for S100β was above that threshold. For 
3D volume renderings, LAS X 3D (Leica Microsystems) 
module was used. For 3D surface renderings, Imaris Viewer 
(Oxford Instruments) was used.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism 
8 (San Diego, USA). Outliers were identified using Grubbs’ 
(alpha = 0.05) or ROUT (Q = 1%) testing. One-way ANOVA 
with post hoc Tukey test or unpaired t test were applied 
for the analysis of in vitro experiments. Non-parametric 
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methods were applied on non-normally distributed data. 
When comparing three or more groups, the Kruskal–Wallis 
test with Dunn’s multiple comparison post-test was used. 
P value of < 0.05 or lower reflected statistical significance.
Results
Characterisation of specificity of novel LRP10 
antibodies
To determine endogenous LRP10 protein expression in cul-
tured cells and human brain tissue, we assessed the specific-
ity of LRP10 antibodies by Western blotting, immunopre-
cipitation, and immunocytochemistry. We generated LRP10 
KO cells in two independent LRP10-expressing cell lines 
(HEK293T and HuTu 80) via CRISPR/Cas9 genome edit-
ing using a single guide RNA (sgRNA) that targets the first 
exon of the LRP10 gene (Online Resource Fig. 1a) [10, 40].
We selected biallelically targeted clonal lines carry-
ing homozygous or compound heterozygous frameshift 
mutations, predicted to result in a premature stop codon 
in LRP10 (KO-1, KO-2, KO-3 in HEK293T or HuTu 80; 
Online Resource Fig. 1b, c) and examined them at the pro-
tein level. Seven commercially available antibodies raised 
against human LRP10 protein (Online Resource Table 4), 
as well as a novel polyclonal antibody recognizing the 
C-terminal domain, hereafter referred to as LRP10-CT 
(Thr463–Thr713, Fig. 1a), were assessed by Western blot-
ting. Out of these in total eight antibodies, one commercial 
antibody (#13228-T16, Sino Biological) directed against the 
N-terminal LRP10 region, hereafter referred to as LRP10-
NT (Met1-Lys440, Fig. 1a), as well as the LRP10-CT anti-
body showed a clear loss of LRP10 signal at the expected 
molecular weight of 100 kDa [18] in protein extracts derived 
from LRP10 KO cells generated in HEK293T cells (Fig. 1b, 
c) or Hutu 80 cells (Online Resource Fig. 1d, e). Interest-
ingly, additional signals detected in the range of 35–50 kDa 
when using the LRP10-CT antibody (Fig. 1c) were absent 
in all LRP10 KO clones and not detected using the LRP10-
NT antibody (Fig. 1b). These bands might be indicative of 
shorter LRP10 isoforms or posttranslational processing of 
the LRP10 protein. Next, we show that both LRP10-NT and 
LRP10-CT antibodies are able to specifically interact with 
endogenous LRP10 protein expressed in HEK293T cells 
under non-denaturing and non-reducing conditions dem-
onstrated by immunoprecipitation of LRP10 protein at the 
expected LRP10 molecular weight that was absent in LRP10 
KO HEK293T cells (Fig. 1d). Finally, both LRP10-NT and 
LRP10-CT antibodies were validated by immunofluores-
cence in wild-type (WT) HuTu 80 cells, showing a vesicle-
like staining pattern, which was absent in HuTu 80 LRP10-
KO cells (Fig.  1e). Additionally, immunofluorescence 
labelling using both LRP10 antibodies simultaneously 
showed vesicle-like staining pattern that fully co-localised 
(Fig. 1f). Taken together, these data validate the LRP10-
NT and LRP10-CT antibodies for sensitive and specific 
detection of the endogenous LRP10 protein under native 
and denaturing conditions, establishing an important tool 
for further characterisation of LRP10 expression in cultured 
cells and in the human brain.
LRP10 expression in adult human brain
We first investigated the LRP10 cellular and regional distri-
bution in the normal adult human brain.
By multi-label immunohistochemistry and confocal 
microscopy on FFPE human midbrain sections, using the 
LRP10-NT antibody, we detected vesicular LRP10 protein 
labelling primarily in S100 calcium-binding β (S100β) posi-
tive, mature astrocytes (Fig. 2a). The majority of LRP10-
immunoreactive vesicles clustered around the perinuclear 
region, and only few co-localised within astrocyte processes 
labelled with glial fibrillary acidic protein (GFAP, Fig. 2f). 
Interestingly, LRP10 immunoreactivity was not detect-
able in dopaminergic neurons of the substantia nigra pars 
compacta (SNpc) (Fig. 2b) or in Iba1-positive microglia 
(Fig. 2c). Positive, weak LRP10 vesicular labelling was 
observed in Quaking 7-positive oligodendrocytes (Fig. 2d). 
Furthermore, we detected strong, diffuse LRP10 immuno-
reactivity in α-SMA-positive vascular smooth muscle cells, 
as well as in cells lining the inner vessel walls, most likely 
representing endothelial cells separated from the vascular 
smooth muscle cells by LRP10-negative endothelial base-
ment membrane in the midbrain neurovasculature (Fig. 2e). 
This pattern of expression is in line with single-cell RNA 
sequencing from mouse neurovasculature [35, 84], reveal-
ing high expression of LRP10 in pericytes, smooth muscle 
cells, vascular fibroblast-like cells, endothelial cells, and 
astrocytes (Online Resource Fig. 3). Next, we analysed the 
astrocytic (S100β-positive) expression of LRP10 in differ-
ent brain regions, including midbrain (SNpc), hippocampus, 
and temporal cortex. Interestingly, LRP10 protein levels cal-
culated as amount of LRP10-immunoreactive vesicles per 
S100β-positive astrocyte were significantly higher in SNpc 
when compared to hippocampus or temporal cortex (Online 
Resource Fig. 2c, d; midbrain vs. temporal cortex, p < 0.001; 
midbrain vs. hippocampus, p < 0.001). This regional differ-
ential LRP10 protein expression is in line with the LRP10 
RNA microarray data obtained from six adult control brain 
donors of African American (2), Hispanic (1), and Cauca-
sian (3) origins (http:// www. human. brain- map/ micro array/ 
search, Allen Brain Atlas). The highest relative LRP10 
gene expression was found in brainstem nuclei, including 
midbrain, whereas low expression was detected in corti-
cal regions, including hippocampus and temporal cortex 
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(Online Resource Fig. 4a). These expression patterns were 
consistent across three LRP10-specific probes. To further 
investigate the striking observation that LRP10 expression 
is high in brain astrocytes, but low in TH-positive dopa-
minergic neurons, we analysed LRP10 protein expression 
in previously established in vitro models generating human 
Fig. 1  Validation of LRP10 antibodies. a LRP10 protein struc-
ture. LRP10 antibodies were raised against the extracellular/luminal 
domain (LRP10-NT: 1–440 aa) or the intracellular/cytosolic domain 
(LRP10-CT: 463–713 aa). CUB, complement C1R/C1S, urchin EGF, 
BMP1; LDLA, low-density lipoprotein receptor class A; TM, trans-
membrane domain; R-rich, arginine-rich domain; P-rich, proline-rich 
domain; YXXφ motif of a tyrosine plus two other amino acids fol-
lowed by an amino acid with a large bulky hydrophobic side chain; 
aa, amino acid. Western blots showing endogenous LRP10 in LRP10 
WT and KO lines (black arrows) using extracellular (b) or intracel-
lular (c) LRP10 antibody for detection. Whole cell lysates were 
obtained from HEK293T clones. Vinculin was used as a reference. 
asterisk, non-specific binding. d Immunoprecipitation of endogenous 
LRP10 from LRP10 WT and KO lines generated in HEK293T using 
both LRP10 antibodies. Input LRP10 was detected using LRP10-
CT antibody. Immunoprecipitation with LRP10-NT, detection with 
LRP10-CT; immunoprecipitation with LRP10-CT, detection with 
LRP10-NT. Asterisk, non-specific binding. e Representative images 
of LRP10 (green) in LRP10 WT and KO lines from HuTu 80 cells. 
f Co-localisation of extracellular (magenta) and intracellular (green) 
LRP10 antibody in HuTu 80 cells. For e and f: maximum intensity 




iPSC-derived astrocytes and ventral midbrain dopaminer-
gic neurons (vmDAN) from a healthy individual (Online 
Resource Fig. 2a) [71]. Robust expression of key markers 
of progenitor cells (99% Nestin, 84% SOX2), vmDAN (58% 
MAP2, 37% FOXA2), and astrocytes (51% AQP4, 60% 
SOX9) using immunocytochemistry confirmed the efficiency 
Fig. 2  LRP10 is highly expressed in astrocytes and neurovascula-
ture. a–e Representative images of LRP10 (green) protein expres-
sion at the cellular level in adult human midbrain. a Astrocytes were 
stained with S100β (magenta). b Dopaminergic neurons were stained 
with TH (magenta). c Microglia were stained with Iba1 (magenta). 
d Oligodendrocytes were stained with Quaking 7 (magenta), an 
RNA-binding protein that is highly specific for myelinating oli-
godendrocytes in the CNS. e Vascular smooth muscle cells were 
stained with α-SMA (magenta). Endothelial basement membrane is 
indicated between yellow, dashed lines. Yellow arrows indicate cells 
positive for either S100β, Iba1, or Quaking 7. f 3D surface render-
ing of LRP10 in astrocyte processes (GFAP, magenta) in adult human 
midbrain. LRP10 vesicle cluster around perinuclear region is indi-
cated with red asterisks. Yellow arrows indicate partial co-localisa-
tion between LRP10 and GFAP. g RT-qPCR analysis of LRP10 and 
SNCA genes in human iPSC-derived progenitors, vmDAN, and astro-
cytes from a control line. Data represent relative normalized mRNA 
expression using primers designed against N-term and C-term of 
LRP10 or SNCA cDNA. CLK2, COPS5, RNF10 were used as refer-
ence genes. Error bars represent ± SEM (N = 3 biological replicates). 
h Representative images of LRP10 protein expression in human 
iPSC-derived dopaminergic neurons (TH) or astrocytes (S100β). 
Representative images from a minimum of three independent differ-
entiations. a–f Representative images from a minimum of three brain 
sections derived from three non-demented individuals. All stainings 
were performed with LRP10-NT antibody. Nuclei were counter-
stained with DAPI (blue). Maximum intensity projections. Scale bars, 
10 µm. vmDAN, ventral midbrain dopaminergic neurons
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of the differentiation protocols used in this study (Online 
Resource Fig. 4b, c). Next, RNA expression analyses by RT-
qPCR in these three different in vitro cell populations (pro-
genitors, vmDAN, astrocytes) demonstrated higher LRP10 
expression in iPSC-derived astrocytes when compared to 
progenitor or vmDAN cultures (Fig. 2g), whereas SNCA 
expression levels were higher in neurons when compared 
to progenitor or astrocyte in vitro cultures (Fig. 2g). Finally, 
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analyses of LRP10 protein expression by immunofluores-
cence using KO-validated LRP10-NT antibody demonstrates 
strong vesicular staining pattern in iPSC-derived astrocytes 
(Fig. 2h). This strong LRP10 immunoreactivity was not 
detected in vmDAN (Fig. 2h). Taken together, these data 
show that LRP10 expression is mainly restricted to non-neu-
ronal cells (including astrocytes and neurovasculature resi-
dent cells) in vivo, and this differential astrocyte-enriched 
LRP10 expression is maintained in our in vitro model of 
human iPSC-derived vmDAN and astrocytes.
Endogenous LRP10 mainly co‑localises with early 
endosomes and the retromer complex
Our immunohistochemical experiments on human brain tis-
sue showing vesicular LRP10 localisation (Fig. 2a, f) are 
in line with previous studies demonstrating that in vari-
ous cell types, overexpressed and tagged LRP10 proteins 
mainly localise to the trans-Golgi network, endosomes, and 
the retromer complex [15, 18, 26, 70]. As the presence of 
protein tags and protein overexpression by itself can inter-
fere with physiological protein localisation, we next set out 
to determine the subcellular localisation of endogenously 
expressed LRP10 protein using LRP10-NT antibody in com-
bination with antibodies labelling organelle-specific pro-
teins. In iPSC-derived astrocytes from a healthy individual, 
we detected strong co-localisation of LRP10 with the early 
endosomal marker EEA1 (Fig. 3a) and the retromer marker 
VPS35 (Fig. 3b). Furthermore, at the perinuclear region, 
LRP10 co-localised with the trans-Golgi network marker 
TGN46 (Fig. 3c). LRP10-labelled structures co-localised 
to a lesser extend with lysosome-associated membrane 
protein 1 (LAMP-1, Fig. 3d, e). To quantify the degree of 
overlap between LRP10 and various subcellular markers, 
the Manders Overlap Coefficient was calculated (Fig. 3e) 
showing the highest LRP10 co-localisation with early 
endosomes and the retromer (mean (SD); LRP10-EEA1: 
0.42 (0.13); LRP10-VPS35: 0.34 (0.12); EEA1 vs. VPS35, 
p = 0.08) and moderate overlap with the trans-Golgi network 
[mean (SD); LRP10-TGN46: 0.27 (0.14)]. The degree of 
the LRP10 overlap with LAMP-1 was significantly lower 
when compared to EEA1, TGN46, or VPS35 (TGN46 vs. 
LAMP-1, p < 0.001; EEA1 vs. LAMP-1, p < 0.001; VPS35 
vs. LAMP1, p < 0.001). To test whether endogenous LRP10 
is localised to the PM, we incubated non-permeabilized cells 
at 4 °C with the LRP10-NT antibody, directed against the 
predicted extracellular/luminal domain of LRP10 [18], to 
specifically label PM-localised LRP10 proteins. Indeed, we 
detected diffuse as well as clustered LRP10-staining at the 
PM (Fig. 3f, panels II, III, and IV). In contrast, permea-
bilized astrocytes demonstrated high expression of nuclear 
localised astrocyte-enriched transcription factor SOX9 and 
LRP10-positive intracellular vesicles (Fig.  3f, panel I). 
These results are in line with previous overexpression stud-
ies and suggest that the normal trafficking routes of LRP10 
involve shuttling from the Golgi apparatus to the PM, where 
after internalization LRP10 is transported to endosomes. 
From the endosomes, it can be either retrogradely trans-
ported through the retromer complex to the Golgi, or tar-
geted via late endosomes towards lysosomes for its final 
degradation.
LRP10 is a novel SORL1‑interacting protein
The subcellular localisation of LRP10 described in this 
study, combined with the earlier proposed model for LRP10 
as a sorting receptor for the amyloid precursor protein (APP) 
[18] and apolipoprotein E (APOE) internalization [19] 
show similarities with subcellular localisation and function 
of another member of the LDL-receptor family—SORL1. 
Interestingly, SORL1 has been genetically and function-
ally associated with AD [5, 74]. Because of these observed 
similarities and previously reported interactions between 
SORL1 and other members of the LDL-receptor fam-
ily [79], we hypothesise that LRP10 and SORL1 proteins 
Fig. 3  LRP10 is localised to vesicular structures and interacts with 
SORL1. a–d Deconvolved confocal images of LRP10 (green) co-
localisation with various subcellular markers in 8  weeks old iPSC-
derived astrocytes. a Early endosomes were detected using anti-
EEA1 antibody (magenta). b The retromer complex was stained 
with anti-VPS35 antibody (magenta). c Trans-Golgi was stained 
with anti-TGN46 (magenta). d Lysosome-associated membrane pro-
tein 1 (LAMP-1) was used to detect lysosomal vesicles. a–d Zoomed 
images represent magnified views of boxed areas in the perinuclear 
region. Co-localisation with LRP10 is indicated by yellow arrow-
heads. Scale bars, 10 µm. e Quantification of LRP10 co-localisation 
with various subcellular markers. Thresholded Manders Overlap 
Coefficient is plotted on the y-axis. Per condition, 35 cells analysed. 
Error bars represent mean ± SD, one-way ANOVA with post hoc 
Tukey test; n.s., not significant; ***p < 0.001. f 11 weeks old human 
iPSC-derived astrocytes (SOX9+, magenta) were permeabilized and 
stained for intracellular LRP10 (green). For panels I and II: astro-
cytes were pre-incubated on ice to arrest endocytosis. Cell surface 
LRP10 molecules at the plasma membrane (PM) were labelled with 
LRP10-NT antibody. Scale bars, 10 µm. g, h Representative LRP10 
(green) and SORL1 (magenta) co-localisation in iPSC-derived astro-
cytes (g) or in adult human midbrain (h). Images represent magnified 
views of boxed areas in the perinuclear region. Representative images 
from a minimum of three differentiations or three brain sections 
derived from three different non-demented individuals. Co-local-
isation LRP10 with SORL1 is indicated by yellow arrowheads. i–k 
HEK293T LRP10-KO or WT cells were transiently co-transfected 
with untagged full-length SORL1 only or together with N-terminally 
V5-tagged full-length LRP10. Total cell lysates (input) were sub-
jected to immunoprecipitation with antibodies against SORL1 and 
LRP10. SORL1 antibody detected several bands (> 180  kDa) of 
overexpressed full-length SORL1 protein. Mouse IgG was used as a 
negative control. Immune complexes were resolved by SDS-PAGE, 
followed by Western blotting. a–d, f–h All stainings were performed 
with LRP10-NT antibody. Nuclei were counterstained with DAPI 




physically interact to form a receptor complex. To test this 
hypothesis, we first looked at their co-localisation in vitro 
and in vivo using immunocytochemistry and immunohisto-
chemistry, respectively. Interestingly, both in iPSC-derived 
astrocytes (Fig. 3g) as well as in midbrain sections from 
control subjects (Fig. 3h), we detected high levels of overlap 
between SORL1 and LRP10 immunoreactivity, suggestive 
of a potential physical interaction between them. Next, to 
determine whether LRP10 and SORL1 are part of the same 
protein complex, we performed co-immunoprecipitation 
experiments. First, protein extracts from WT HEK293T 
cells expressing full-length V5-tagged LRP10 together 
with untagged full-length SORL1 (Fig. 3i, INPUT WT) or 
untagged full-length SORL1 alone (Fig. 3i, INPUT KO) 
were used as an input for co-immunoprecipitation experi-
ments. Interestingly, using a mouse anti-SORL1 antibody, 
V5-LRP10 co-immunoprecipitated with untagged SORL1, 
but could not be detected using a nonimmune mouse immu-
noglobulin (IgG) as a negative control (Fig. 3j). Further-
more, the interaction between LRP10 and SORL1 was con-
firmed using HEK293T WT and LRP10 KO lines that were 
only transfected with the full-length untagged SORL1 plas-
mid (Fig. 3i, INPUT KO). Using the LRP10-NT antibody, 
SORL1 co-immunoprecipitated with V5-LRP10 in WT 
cells, whereas only low levels of SORL1 were co-immu-
noprecipitated in the LRP10 KO protein extracts (Fig. 3k). 
These results are in support of our hypothesis, that LRP10 
and SORL1 are part of the same protein complex, providing 
new insights into their potential roles in shared pathogenic 
pathways in neurodegenerative disorders.
Enlarged LRP10‑positive vesicles are detected 
in brain of the LRP10 p.Arg235Cys variant carrier
To investigate the role of LRP10 in LBD pathogenesis, 
LRP10 expression was compared in autopsy-derived brain 
material from LRP10 variant carrying patients, idiopathic 
PD cases, and age- and sex-matched control subjects (Online 
Resource Table 1). LRP10 mRNA expression was unaltered 
in SNpc material from the idiopathic PD cohort (PD IV-IX, 
N = 6) when compared to non-demented controls (NDC 
VI-XI, N = 6) (Online Resource Fig. 5). Detailed clinical 
and pathological features of a total of five donors carrying 
rare, pathogenic variants in LRP10 included in this study 
have been analysed elsewhere and are summarized in the 
materials and methods section [70, 86]. A severe burden of 
Lewy body pathology with the highest Braak α-synuclein 
stage was present in all these five LRP10 carriers in the 
brainstem, limbic, and neocortical areas [70, 86]. To deter-
mine whether LRP10 pathogenic variants affect LRP10 
expression, we first analysed LRP10 staining intensity 
and area in midbrain sections derived from three different 
cohorts: non-demented controls (NDC, N = 4), idiopathic 
PD cases (N = 3), and LRP10 variant carriers (patients I–V 
(N = 5); Online Resource Table 1) by immunohistochem-
istry using the LRP10-NT antibody. LRP10-positive vesi-
cles were observed in a subset of SNpc cells from NDC, 
PD, and LRP10 variant carriers (Fig. 4a, b). Although no 
apparent differences in size and staining intensity in LRP10-
positive vesicles were observed between LRP10-express-
ing cells from NDC, PD and the majority of LRP10 vari-
ant carriers, we observed significantly larger and clustered 
LRP10-positive vesicles in the brainstem tissue from the 
LRP10 p.Arg235Cys variant carrier (patient III, Fig. 4c; 
NDC I/II/III/IV vs. p.Arg235Cys, p < 0.001; PD I/II/III vs. 
p.Arg235Cys, p < 0.001; p.Arg151Cys/p.Ala212Ser fs*17/p.
Gly453Ser/p.Asn517del vs. p.Arg235Cys, p < 0.001). Fur-
ther analysis of the LRP10 vesicles in patient III by re-scan 
confocal microscopy [23] revealed donut-shaped vesicles, 
with a large lumen (Fig. 4d), reminiscent of enlarged and 
damaged lysosomes [13, 28].
LRP10 is present in the core of Lewy bodies
To further determine the role of LRP10 in Lewy pathology, 
we analysed LRP10 protein expression and localisation in 
relationship to LB-containing neurons in brain specimens 
obtained from the LRP10 variant carriers, idiopathic PD 
and DLB patients. The ring-shaped appearance of strong 
peripheral α-synuclein immunoreactivity and a weakly 
stained core typical of brainstem-type, mature LBs were 
revealed in neuromelanin-positive cells of SNpc sections 
from all analysed cases using a validated immunohisto-
chemical staining protocol for α-synuclein (SYN-1) antibody 
[66, 82]. Strikingly, co-staining of LRP10 and α-synuclein 
demonstrated the presence of LRP10 immunoreactivity in 
the core of brainstem-type, mature LBs in SNpc from all 
LRP10 variant carriers as well as idiopathic PD and DLB 
patients (Fig. 5a, b). Quantification of LRP10-positive LB 
in neuromelanin-containing neurons demonstrated a high 
percentage of LRP10-positive LBs (71–91%, mean = 86% 
LRP10 + LB (N = 200), Fig. 5c). In temporal cortex and 
medial frontal gyrus (Online Resource Fig. 6) from a total 
of seven brain donors, we only found few cortical LBs with 
weaker LRP10 immunoreactivity in the form of sparse vesi-
cles (Online Resource Fig. 6c) or diffuse staining in the core 
of a targetoid cortical LB (Online Resource Fig. 6d). Taken 
together, these data identify LRP10 as a novel LB-resident 
protein mainly found in brainstem-type Lewy pathology. 
LRP10 protein is detected at late LB maturation 
stages
Different LB maturation stages associated with LB pathol-
ogy in PD and DLB have been described to reflect LB 
morphogenesis [44]. We, therefore, characterised at what 
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LB maturation stage LRP10 protein is incorporated into 
nigral LBs using co-staining of LRP10 and α-synuclein. 
First, we identified 6 LB maturation stages (Fig. 6a) based 
on α-synuclein staining patterns, including cytoplasmic, 
punctuate pattern (1), punctuate pattern with a starting 
α-synuclein aggregation centre (2), large, proteinaceous 
accumulations, termed pale bodies (PB) (3), a combination 
of irregular accumulation with a progressive condensation 
into a compact LB-type of inclusion (4), cytoplasmic, punc-
tuate α-synuclein pattern with a defined and compact LB 
(5), mature LB (6) (Fig. 6a, panels 1–6). LRP10 was not 
detected in neuromelanin-containing dopaminergic neurons 
containing stage 1 and 2 types of α-synuclein-positive inclu-
sions (Fig. 6a, panels 1 and 2). However, sparse LRP10-
positive vesicles could be detected in neurons containing 
PB-type inclusions (Fig. 6a, panel 3). Interestingly, as the 
condensation of α-synuclein aggregates progressed to stage 
4, LRP10 immunoreactivity was observed in the centre of 
immature inclusions (Fig. 6a, panel 4). At the final two 
maturation stages, granular LRP10 staining was detected 
in the LB core of α-synuclein inclusions in neuromelanin-
positive neurons (Fig. 6a, panels 5 and 6). Additionally, we 
used super-resolution microscopy to further characterise the 
presence of LRP10 protein in the core of nigral LBs. With 
this approach, we observed numerous LRP10-positive vesic-
ular structures in the interior of these mature α-synuclein 
inclusions (Online Resource Video 1 and 2). Quantifica-
tion of LRP10 immunoreactivity in α-synuclein inclusions 
revealed that LRP10 is mainly present at the last three stages 
of LB morphogenesis (Fig. 6b; Ntotal = 247, Npunctuate = 51, 
NPB-type = 44, NPB/LB-type or LB-type = 152, p < 0.001). No dif-
ference in the maturation pattern of LRP10 incorporation 
into nigral LB was observed when comparing LB localisa-
tion of LRP10 in idiopathic PD (N = 3) and DLB (N = 3), 
and LRP10 pathogenic variant carriers (N = 5). Finally, 
recent reports demonstrated concentric laminar structure 
of LBs as identified by staining using α-synuclein antibod-
ies targeting different α-synuclein domains [60]. Moreover, 
Fig. 4  Enlarged LRP10-positive vesicles detected in brain of the 
LRP10 p.Arg235Cys variant carrier. a, b Representative images 
of LRP10 vesicle morphology from NDC (N = 4 individuals), PD 
(N = 3 individuals) (a), and five patients carrying LRP10 patho-
genic variants (b). Enlarged and clustered LRP10 vesicles were 
seen in the midbrain of the PDD patient carrying p.Arg235Cys 
variant (white arrowheads). Representative images from a mini-
mum of three brain sections. Nuclei were counterstained with DAPI 
(blue). Maximum intensity projections. All stainings were per-
formed with the LRP10-NT antibody. Scale bars, 10  µm. c Quanti-
fication of surface area (µm2) of LRP10-postive vesicles in controls, 
idiopathic PD and LRP10 variants carriers. Each value in the scat-
ter dot plots represents the average vesicle size/cell. Kruskal–Wal-
lis with Dunn multiple comparison post hoc; ***p < 0.001. N equals 
the number of cells analysed per brain specimen. NNDC I = 108, 
NNDC II = 157, NNDC III = 112, NNDC IV = 58, NPD I = 112, NPD II = 96, 
NPD III = 80, Np.Arg151Cys = 87, Np.Ala212Ser fs*17 = 89, Np.Arg235Cys = 83, 
Np.Gly453Ser = 85, Np.Asn517del = 74. d High-resolution, re-scan confocal 
images of LRP10 vesicles reveal enlarged donut-like morphology in 
the PDD patient carrying p.Arg235Cys variant when compared to a 
non-demented control, scale bars 2 µm
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Fig. 5  LRP10 immunoreactivity in the core of nigral Lewy bodies. 
a, b Double labelling of α-synuclein (SYN-1, magenta) with LRP10 
(green) antibody recognizing the intracellular domain. LRP10 immu-
noreactivity is present in the core of a LB in neuromelanin-positive 
dopaminergic neurons of SNpc (bright-field images). Representative 
confocal images of nigral LBs in patients carrying LRP10 mutations 
(a), or idiopathic PD and DLB (b). Maximum intensity projections. 
Scale bars, 10 µm. c Quantification of percentages of LRP10 immu-
noreactivity in more mature PB/LB-type or LB-type of α-synuclein 
inclusions. All inclusions analysed were found in neuromelanin-con-
taining dopaminergic neurons of substantia nigra. N = 20 LB per indi-
vidual; NDLB = 3 individuals (60 LB); NPD = 2 individuals (40 LB). 
Error bars represent mean ± SD. LB, Lewy body
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patterns of vesicular structures and dysmorphic organelles 
have been detected in Lewy pathology [76]. We performed 
multi-label microscopy including markers for lysosomal 
proteins, LAMP1 and LAMP2, and an early endocytic 
marker RAB5A to determine in more detail LRP10 protein 
localisation within the LBs with respect to organelle mark-
ers. Interestingly, these markers showed a distinct pattern 
characterised by concentric laminations in mature LBs, with 
LRP10 being consistently localised in the LB core, furthest 
from the periphery (Online Resource Fig. 7). These distinct 
patterns of incorporation and localisation of LRP10-positive 
vesicles in the core of mature LBs suggest an organized pro-
cessing and mechanistic links between vesicle trafficking 
and α-synuclein inclusion formation in LBD.
Discussion
A growing amount of genetic evidence supports the involve-
ment of LRP10 gene variants in the development of inherited 
forms of PD, PD with dementia, and DLB [20, 70, 86, 88]. In 
the present study, we provide novel insights into the expres-
sion and potential function of LRP10 in vitro and human 
brains in physiological and pathological conditions. Using 
novel, KO-validated and biochemically characterised LRP10 
antibodies, we demonstrate the molecular characteristics, as 
well as brain regional, cellular, and subcellular localisation 
patterns of endogenously expressed LRP10 protein in iPSCs 
and human brain tissue.
LRP10 is a single-pass transmembrane protein and a dis-
tant relative of the LDL-receptor family with a predicted 
molecular weight of 76 kDa [67]. Yet, a higher molecu-
lar weight band of approximately 100 kDa is consistently 
detected by Western blotting using both LRP10-NT and 
LRP10-CT antibodies (Fig. 1b, c). This is likely caused 
by posttranslational modifications, as LRP10 has several 
predicted N-glycosylation sites and a phosphorylation site 
(http:// unipr ot. org). Interestingly, only the LRP10-CT anti-
body detects additional proteins in the range of 35–50 kDa, 
which are not detected in LRP10 KO cell lines. These frag-
ments suggest the presence of other LRP10 isoforms pos-
sibly lacking the epitope detected by the LRP10-NT anti-
body. Two other protein isoforms of human LRP10 have 
been reported in addition to its full-length transcript (https:// 
www. prote inatl as. org/ ENSG0 00001 97324- LRP10). How-
ever, these isoforms lack a large portion of the C-terminal 
region of LRP10, which is detected by the LRP10-CT anti-
body, and the molecular weight of these isoforms would be 
larger than the fragments detected here by Western blot-
ting, making it unlikely that the detected 35–50 kDa prod-
ucts correspond to the above-mentioned LRP10 isoforms. 
Interestingly, it has been shown that some members of the 
Fig. 6  Incorporation of LRP10 into α-synuclein inclusions during 
LB formation. a. Representative confocal images of morphological 
spectrum of α-synuclein (SYN-1, magenta) inclusion formation (steps 
1–6). LRP10 (green) incorporation is present in more mature PB/LB 
or LB-type of α-synuclein inclusions. 1. Intracytoplasmic, punctu-
ate α-synuclein. 2. Intracytoplasmic, punctuate α-synuclein with an 
aggregation centre (arrow). 3. PB-type: less compact, unstructured 
α-synuclein inclusion. Arrow heads and zoomed area indicate LRP10 
vesicles. 4. Intracytoplasmic α-synuclein network containing PB 
(asterisk) and more compact LB-type inclusions (arrow). 5. Intracyto-
plasmic α-synuclein network with LB-type inclusion. 6. Mature LB. 
Maximum intensity projections. Scale bars, 10  µm. Representative 
images from a total of 247 nigral α-synuclein inclusions imaged. All 
inclusions analyzed were found in neuromelanin-containing dopamin-
ergic neurons of substantia nigra. b Percentages of LRP10 immuno-
reactivity in different patterns of α-synuclein inclusions. Ntotal = 247; 
Npunctuate = 51; NPB-type = 44; NPB/LB-type or LB-type = 152. Kruskal–
Wallis with Dunn multiple comparisons test; n.s., not significant; 
***p < 0.001. LB, Lewy body. PB, pale body
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LDL-receptor family can be processed at the cell surface by 
metalloproteinases (e.g. ADAM10) or secretases (BACE1 
or γ-secretase), producing different protein fragments with 
various physiological functions [6, 67]. Further studies are 
needed to understand whether LRP10 undergoes proteolytic 
cleavage, and if so, what are the involved proteases and the 
physiological functions of LRP10 processed fragments.
Next, our expression analysis demonstrates that LRP10 
is detected in non-neuronal cells with the highest expres-
sion levels in astrocytes and neurovascular unit in the adult 
human brain (Fig. 2 and Online Resource Fig. 3). Strik-
ingly, we were unable to detect LRP10 signal in unaffected 
dopaminergic neurons in control subjects. This differential 
expression was also observed in iPSC-derived vmDAN and 
astrocytes, lacking or highly expressing LRP10, respectively. 
These findings are in line with publicly available online tran-
scriptomic bulk and single-cell RNA expression databases, 
showing the highest LRP10 expression in mature astrocytes 
and lack of its expression in neurons [9, 45, 93]. We also 
provide evidence of differential astrocytic LRP10 protein 
expression in different brain regions, showing higher lev-
els in the brainstem when compared to the hippocampus or 
temporal cortex in physiological conditions. This is also in 
line with expression data in existing databases, demonstrat-
ing that LRP10 mRNA is highly expressed in the midbrain 
and diencephalon, as well as the dorsal motor nucleus of the 
vagus nerve, raphe nuclei, and coeruleus–subcoeruleus com-
plex. Interestingly, these brain regions are proposed to be 
involved in the early stages of PD [16], suggesting therefore, 
a potential involvement of LRP10 in the selective regional 
vulnerability during the disease progression.
The specific LRP10 expression patterns suggest a prom-
inent role of non-neuronal LRP10-mediated pathways in 
LBD pathophysiology where various disease mechanisms 
could be involved. First, astrocytes are essential in provid-
ing a trophic environment for neurons by secreting survival 
factors [8, 51], regulating synaptic functions [4], controlling 
brain homeostasis [78], and maintaining the blood–brain 
barrier (BBB) [2]. Disturbances of these neuron survival-
promoting functions by astrocytes have been described in 
PD [51, 58]. Alternatively, astrocytes can also become reac-
tive via a variety of challenges, such as activation by micro-
glia, ageing, and neurodegeneration, generating an A1 astro-
cyte population with neurotoxic properties [21, 50]. These 
A1 astrocytes have been shown to be increased in major 
neurodegenerative disorders, including PD [50]. Addition-
ally, a drug-mediated blockage of A1 astrocyte activation by 
pathological α-synuclein has been suggested to be neuropro-
tective in PD [91]. Interestingly, LRP10 levels appear to be 
increased in A1 reactive astrocytes when compared to naïve 
(A0) astrocytes (https:// nyscf seq. appsp ot. com/). Further-
more, astrocytes have been shown to regulate the cell-to-cell 
transfer of α-synuclein through various mechanisms [47, 73, 
90]. Astrocytes can internalise α-synuclein, which can sub-
sequently be processed via the autophagy–lysosome path-
way, highlighting the importance of astrocytic α-synuclein 
removal and degradation in LBD [25, 55, 80]. Additionally, 
recent studies provide accumulating evidence that other PD 
genes play important roles in astrocyte biology, and their 
dysfunction might lead to neuronal α-synuclein aggregation 
and neuronal loss by non-cell autonomous mechanisms [14]. 
Based on our findings, we speculate that LRP10 could be 
involved in internalisation, degradation or cell-to-cell trans-
port of α-synuclein by astrocytes.
In addition to astrocytes, we show high LRP10 expression 
in the neurovasculature, which plays an essential role in the 
clearance of proteins prone to aggregation, e.g. amyloid beta 
(Aβ) and possibly α-synuclein [11, 89]. Interestingly, other 
lipoprotein receptors (e.g. LRP1) have been shown to play 
important roles in the clearance of Aβ across the BBB [24]. 
Moreover, it has been suggested that LRP10 is an APP sort-
ing receptor and reduced LRP10 levels lead to an increase in 
Aβ production [18]. Hence, similar to LRP1, LRP10 might 
play a role in the processing and clearance of aggregation-
prone proteins at the gliovascular interface. We detect high 
LRP10 expression at various cellular components of the 
BBB, including endothelial and smooth muscle cell layers 
of the neurovasculature. Functional roles for LRP10 at the 
neurovasculature and BBB and whether LRP10 variants con-
tribute to neurovascular or BBB dysfunction in LBD remain 
to be experimentally tested.
We show that endogenously expressed LRP10 localises 
to various subcellular compartments, including trans-Golgi, 
endosomes, plasma membrane, retromer, and, to a lesser 
extent, lysosomes. These data point towards deregulated 
intracellular trafficking pathways in PD and DLB patients 
harbouring loss-of-function variants in the LRP10 gene. 
Recent advanced microscopic and genetic studies have 
brought forward a central role for impaired vesicle traffick-
ing in PD’s pathogenesis [29, 76]. Interestingly, other PD-
related genes such as LRRK2, VPS35, and GBA play essen-
tial roles in astrocytes, and it has been shown that variants 
in these genes lead to impairments in intracellular vesicle 
trafficking, dopaminergic neuron degeneration, and accu-
mulation of toxic α-synuclein species in surviving neurons 
and glia [3]. Whether the non-neuronal expression of LRP10 
disease-associated variants leads to changes in intracellular 
vesicle trafficking needs to be further investigated.
Based on the data from this study and previous reports, 
LRP10 expression and its association with neurodegenera-
tive diseases demonstrate a high degree of overlap with 
SORL1, an established causative gene and risk factor in 
AD [38, 72]. First, both LRP10 and SORL1 are transmem-
brane proteins that function at the plasma membrane and in 
intracellular vesicles, where they both mediate trafficking 
of APP to protect it from amyloidogenic processing [5, 18]. 
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Next, both LRP10 and SORL1 need the retromer for the 
endosomal sorting, and when this interaction is abolished, 
LRP10 and SORL1 do not reach the plasma membrane [30, 
81]. Here, we show strong co-localisation and protein–pro-
tein interaction between LRP10 and SORL1, providing 
evidence for converging functional pathways. How SORL1 
and LRP10 functionally interact and how this interaction 
is affected by disease-associated LRP10 and SORL1 in 
LBD and AD variants remain to be determined. Our find-
ing provides novel and exciting evidence of intriguing links 
between these proteins and the role of transmembrane pro-
tein sorting mechanisms in the development of neurodegen-
erative disorders, including PD, DLB, and AD.
To better understand the role of LRP10 expression in the 
diseased brain, we analysed LRP10 protein expression in 
brain specimens from five patients carrying heterozygous 
variants in the LRP10 gene (p.Arg151Cys, p.Ala212Ser 
fs*17, p.Arg235Cys, p.Gly453Ser, p.Asn517del) with var-
ying phenotypes from a typical late-onset PD to PD with 
dementia, or DLB. In most LRP10 variant carriers, we did 
not observe significant changes in LRP10 vesicular stain-
ing patterns or area in comparison to NDC or idiopathic 
PD brain samples. However, in the SNpc material from the 
p.Arg235Cys variant carrier, donut-shaped LRP10-positive 
vesicles with significantly enlarged lumen were found. 
While we were unable to determine the precise identity of 
these enlarged vesicular structures, intriguingly, LRRK2 
has been shown to regulate the size and number of lys-
osomes in primary mouse astrocytes, and mutant LRRK2 
is recruited onto enlarged lysosomes [28, 37]. Furthermore, 
loss of SORL1 leads to enlarged early endosomes [42]. Both 
LRRK2 and SORL1 phenotypes are similar to the LRP10-
positive structures observed in the p.Arg235Cys variant car-
rier in this study, pointing towards a potential impairment 
of endo-lysosomal pathways in patients with this variant. 
However, these results are based on a single brain, and they 
need to be interpreted with caution. Therefore, analyses of 
other carriers are warranted.
Comparing post-mortem tissues from controls and idi-
opathic PD, we show no significant differences in LRP10 
mRNA levels in substantia nigra. Additionally, LRP10-
positive intracellular vesicle number and morphology were 
unaltered in the idiopathic PD cohort when compared to 
NDC. Other studies reporting on LRP10 expression levels in 
other neurodegenerative diseases show inconsistent results. 
A previous study found no significant difference between 
LRP10 mRNA levels in patients with AD and controls but 
significantly reduced LRP10 protein expression was detected 
in the frontal cortex and hippocampus of AD brains by West-
ern blotting [18]. It should be noted that the LRP10 antibody 
used in that study did not pass our antibody validation test 
for detecting the endogenous LRP10 protein. Additionally, 
LRP10 signals in AD and control samples were normalized 
to the neuronal Tuj1 protein, whereas based on our findings, 
normalization with general or astrocytic markers would have 
been more appropriate. Furthermore, a systematic multi-
cohort transcriptomic analysis of post-mortem brain tissue 
from AD, Huntington’s disease (HD), PD, and ALS detected 
increased levels of LRP10 in astrocytes in these neurodegen-
erative disorders [49]. Finally, a recent transcriptomic study 
on extensive AD cohorts demonstrated that LRP10 acts as 
a key driver of specific molecular subtypes of AD, with its 
expression being, either upregulated or downregulated in 
astrocytes, endothelial cells and microglia, depending on the 
AD subtype analysed [62]. Based on these studies and our 
findings, additional work to completely characterise LRP10 
protein expression in brains of LBD and other neurodegen-
erative diseases is warranted.
Recent studies highlighted the presence of vesicles, frag-
mented organellar components, and lipids in LBs [57, 60, 
76]. Moreover, various proteins implicated in the devel-
opment of PD and related LB disorders, e.g. LRRK2 and 
GBA, are present in α-synuclein inclusions [32, 33]. Here, 
we detected LRP10-positive vesicle clustering in the core of 
brainstem-type mature LBs from idiopathic PD and DLB, 
as well as LRP10 variant carriers. This observation suggests 
that LRP10-positive vesicles are either passively trapped in 
the core during LB maturation or could potentially play a 
more active role in LB growth. Furthermore, as the LRP10-
specific antibodies used in our study cannot distinguish 
between WT and mutant protein, it remains unclear whether 
both proteins are localised to mature LBs. Interestingly, we 
found that LRP10 was barely detectable in cortical LBs, in 
keeping with the argument that they represent a less mature 
state when compared to brainstem type of LBs. Our data are 
also in line with another study, where LRP10 was not listed 
among 300 identified proteins in cortical LBs [48]. Further-
more, additional research is required to fully characterise 
LRP10 localisation in α-synuclein inclusions in all major 
synucleinopathies. In particular, it would be interesting to 
determine LRP10 localisation in α-synuclein-positive glial 
cytoplasmic inclusions (GCIs) in multiple system atrophy 
(MSA) and to understand whether LRP10 accumulation is 
only specific to mature brainstem-type LBs in PD and DLB.
We detected distinct LRP10-positive vesicle arrange-
ments associated with various α-synuclein aggregation pat-
terns in neuromelanin-containing dopaminergic neurons, 
reflecting previously described LB maturation stages [44]. 
Therefore, we speculate that LRP10 vesicles are undetecta-
ble in healthy dopaminergic neurons or at the initial stages of 
LB formation due to a very low abundance of LRP10 in neu-
ronal cells and a still properly functioning degradation sys-
tem. Subsequently, as the protein degradation systems (e.g. 
ubiquitin–proteasome and autophagy–lysosomal pathway) 
collapse and alignment of aggregated α-synuclein proceeds, 
LB morphogenesis progresses and LRP10 becomes apparent 
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in the neuronal soma. At the final stages of LB remodel-
ling and condensation, LRP10-positive vesicles aggregate 
in the core of LB together with other organellar components 
and lipids. This model of LRP10 incorporation into brain-
stem-type LBs requires either neuronal expressed LRP10 
protein or LRP10 secretion by non-neuronal cells and its 
internalisation by neurons from the interstitial space towards 
LB morphogenesis. First, we speculate that if LB localised 
LRP10-positive vesicles have a neuronal origin, they could 
become apparent only during pathological conditions either 
via increased LRP10 expression or via impaired degrada-
tive processes in neurons during disease. We do not have 
evidence that LRP10 expression increases in PD patients 
(Online Resource Fig. 5). However, evidence for impaired 
degradative function has been reported. For instance, 
α-synuclein pathology and reduced GBA function have 
been linked to impairment of the autophagy–lysosomal path-
way [7, 56, 75]. Interestingly, previous work demonstrated 
LRP10 degradation via the autophagy–lysosomal pathway 
[17]. Whether reduced degradative capacity in diseased 
neurons leads to LRP10 accumulation needs to be further 
investigated. Alternatively, LRP10-positive vesicle accumu-
lation in LB could have a non-neuronal origin. Extensive 
neuron-glia coupling, including the exchange of lipids and 
proteins, extracellular vesicles, and mitochondria from astro-
cytes to neurons, have been described [34, 39, 53]. Interest-
ingly, co-culture of PD astrocytes and unaffected control 
vmDANs leads to neurodegeneration and abnormal accu-
mulation of astrocyte-derived α-synuclein [25]. Whether 
astrocyte-derived LRP10 can accumulate in vmDANs and 
cause pathology needs to be further investigated. Irrespec-
tive of the origin of the LRP10-positive vesicles in LB, our 
findings align with the previous observation that the LBs 
core consists of α-synuclein and lipid vesicle clusters [76]. 
Further research is required to clarify the source of LRP10 
protein in neurons and the mechanisms leading to LRP10 
protein accumulation in neuronal LB pathology.
In conclusion, we demonstrate that the LBD-associated 
protein LRP10 is expressed in the intracellular vesicle traf-
ficking compartment of mainly astrocytes, where it can 
interact with the sorting receptor SORL1. Together with 
the finding that LRP10-positive vesicles are at the core 
of mature LB in substantia nigra of PD and DLB brains, 
this study provides further proof of an important role for 
LRP10 in LBD pathogenetic pathways, possibly via cell 
non-autonomous mechanisms. Further research is war-
ranted to illuminate the disease mechanisms regulated by 
LRP10 in neurodegenerative disorders and potentially pro-
vide novel avenues for therapy development.
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